Is GW Pharmaceuticals Stock a Buy?
There's no one way to invest in the cannabis industry. You might pick pot producers, companies with just slight exposure to the industry, or medical marijuana stocks. GW Pharmaceuticals (NASDAQ: GWPH) falls into the medical marijuana segment, but it's also a pharmaceutical company, making it an intriguing option.
The stock's been producing some impressive sales numbers over the past year, but for risk-averse investors, it may be too dependent on the success of just one drug. Let's take a closer look to see whether you should add the stock to your portfolio today.
One danger of investing in the pharmaceutical industry is that a stock's success often hinges on just one drug. GW Pharmaceuticals is no exception. Its Epidiolex drug, which treats Dravet Syndrome and Lennox-Gastaut syndrome, is a crucial part of its business. Right now, the linchpin drug is driving significant growth for the U.K.-based company. It still has many exciting growth opportunities available in the U.S. and Europe.
Source Fool.com
